{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:32:07Z","timestamp":1792024327067,"version":"4.4.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"DOI":"10.7759\/cureus.81264","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T07:41:11Z","timestamp":1743061271000},"source":"Crossref","is-referenced-by-count":13,"title":["Causes, Diagnosis, Treatment, and Prognosis of Cardiac Fibrosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Hasan A","family":"BaniHani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana H","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada  M","family":"Al Sharaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad A","family":"Al Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad K","family":"Bin Ghalaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad S","family":"Bin Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Holeihel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis NG","year":"2021","unstructured":"Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021, 117:1450-88. 10.1093\/cvr\/cvaa324","journal-title":"Cardiovasc Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2018.07.001","article-title":"Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities","volume":"65","author":"Frangogiannis NG","year":"2019","unstructured":"Frangogiannis NG. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019, 65:70-99. 10.1016\/j.mam.2018.07.001","journal-title":"Mol Aspects Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-013-1349-6","article-title":"The pathogenesis of cardiac fibrosis","volume":"71","author":"Kong P","year":"2014","unstructured":"Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014, 71:549-74. 10.1007\/s00018-013-1349-6","journal-title":"Cell Mol Life Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071716","article-title":"Cardiac fibrosis and fibroblasts","volume":"10","author":"Kurose H","year":"2021","unstructured":"Kurose H. Cardiac fibrosis and fibroblasts. Cells. 2021, 10:1716. 10.3390\/cells10071716","journal-title":"Cells"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23136894","article-title":"Matrix metalloproteinases and their inhibitors in pulmonary fibrosis: EMMPRIN\/CD147 comes into play","volume":"23","author":"Chuli\u00e1-Peris L","year":"2022","unstructured":"Chuli\u00e1-Peris L, Carreres-Rey C, Gabasa M, Alcaraz J, Carretero J, Pereda J. Matrix metalloproteinases and their inhibitors in pulmonary fibrosis: EMMPRIN\/CD147 comes into play. Int J Mol Sci. 2022, 23:6894. 10.3390\/ijms23136894","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00186","article-title":"A clinical perspective of anti-fibrotic therapies for cardiovascular disease","volume":"8","author":"Fang L","year":"2017","unstructured":"Fang L, Murphy AJ, Dart AM. A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol. 2017, 8:186. 10.3389\/fphar.2017.00186","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101194","article-title":"Cardiac fibrosis in heart failure: focus on non-invasive diagnosis and emerging therapeutic strategies","volume":"93","author":"Ravassa S","year":"2023","unstructured":"Ravassa S, L\u00f3pez B, Treibel TA, et al.. Cardiac fibrosis in heart failure: focus on non-invasive diagnosis and emerging therapeutic strategies. Mol Aspects Med. 2023, 93:101194. 10.1016\/j.mam.2023.101194","journal-title":"Mol Aspects Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-09940-0","article-title":"Non-ischemic dilated cardiomyopathy and cardiac fibrosis","volume":"26","author":"Cojan-Minzat BO","year":"2021","unstructured":"Cojan-Minzat BO, Zlibut A, Agoston-Coldea L. Non-ischemic dilated cardiomyopathy and cardiac fibrosis. Heart Fail Rev. 2021, 26:1081-101. 10.1007\/s10741-020-09940-0","journal-title":"Heart Fail Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116004","article-title":"Fibroblast diversity and epigenetic regulation in cardiac fibrosis","volume":"25","author":"Aguado-Alvaro LP","year":"2024","unstructured":"Aguado-Alvaro LP, Garitano N, Pelacho B. Fibroblast diversity and epigenetic regulation in cardiac fibrosis. Int J Mol Sci. 2024, 25:6004. 10.3390\/ijms25116004","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01337-7","article-title":"Dual genetic tracing reveals a unique fibroblast subpopulation modulating cardiac fibrosis","volume":"55","author":"Han M","year":"2023","unstructured":"Han M, Liu Z, Liu L, et al.. Dual genetic tracing reveals a unique fibroblast subpopulation modulating cardiac fibrosis. Nat Genet. 2023, 55:665-78. 10.1038\/s41588-023-01337-7","journal-title":"Nat Genet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae044","article-title":"Cardiac and perivascular myofibroblasts, matrifibrocytes, and immune fibrocytes in hypertension; commonalities and differences with other cardiovascular diseases","volume":"120","author":"Torimoto K","year":"2024","unstructured":"Torimoto K, Elliott K, Nakayama Y, Yanagisawa H, Eguchi S. Cardiac and perivascular myofibroblasts, matrifibrocytes, and immune fibrocytes in hypertension; commonalities and differences with other cardiovascular diseases. Cardiovasc Res. 2024, 120:567-80. 10.1093\/cvr\/cvae044","journal-title":"Cardiovasc Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044557","article-title":"Single-cell RNA sequencing analysis reveals a crucial role for CTHRC1 (collagen triple helix repeat containing 1) cardiac fibroblasts after myocardial infarction","volume":"142","author":"Ruiz-Villalba A","year":"2020","unstructured":"Ruiz-Villalba A, Romero JP, Hern\u00e1ndez SC, et al.. Single-cell RNA sequencing analysis reveals a crucial role for CTHRC1 (collagen triple helix repeat containing 1) cardiac fibroblasts after myocardial infarction. Circulation. 2020, 142:1831-47. 10.1161\/CIRCULATIONAHA.119.044557","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08008-5","article-title":"Targeting immune-fibroblast cell communication in heart failure","volume":"635","author":"Amrute JM","year":"2024","unstructured":"Amrute JM, Luo X, Penna V, et al.. Targeting immune-fibroblast cell communication in heart failure. Nature. 2024, 635:423-33. 10.1038\/s41586-024-08008-5","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127593","article-title":"Epigenetic signatures in cardiac fibrosis: focusing on noncoding RNA regulators as the gatekeepers of cardiac fibroblast identity","volume":"254","author":"Lin LC","year":"2024","unstructured":"Lin LC, Liu ZY, Tu B, et al.. Epigenetic signatures in cardiac fibrosis: focusing on noncoding RNA regulators as the gatekeepers of cardiac fibroblast identity. Int J Biol Macromol. 2024, 254:127593. 10.1016\/j.ijbiomac.2023.127593","journal-title":"Int J Biol Macromol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cells11152347","article-title":"Roles of epigenetics in cardiac fibroblast activation and fibrosis","volume":"11","author":"Shao J","year":"2022","unstructured":"Shao J, Liu J, Zuo S. Roles of epigenetics in cardiac fibroblast activation and fibrosis. Cells. 2022, 11:2347. 10.3390\/cells11152347","journal-title":"Cells"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05516-5","article-title":"Epigenetic regulation of mitochondrial fission and cardiac fibrosis via sFRP3 promoter methylation","volume":"81","author":"Jiang SX","year":"2024","unstructured":"Jiang SX, Zhou ZY, Tu B, et al.. Epigenetic regulation of mitochondrial fission and cardiac fibrosis via sFRP3 promoter methylation. Cell Mol Life Sci. 2024, 81:483. 10.1007\/s00018-024-05516-5","journal-title":"Cell Mol Life Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30078","article-title":"DNMT1 deregulation of SOCS3 axis drives\u00a0cardiac fibroblast\u00a0activation in diabetic cardiac fibrosis","volume":"236","author":"Tao H","year":"2021","unstructured":"Tao H, Shi P, Zhao XD, Xuan HY, Gong WH, Ding XS. DNMT1 deregulation of SOCS3 axis drives\u00a0cardiac fibroblast\u00a0activation in diabetic cardiac fibrosis. J Cell Physiol. 2021, 236:3481-94. 10.1002\/jcp.30078","journal-title":"J Cell Physiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119552","article-title":"Histone deacetylase 3 suppresses the expression of SHP-1 via deacetylation of DNMT1 to promote heart failure","volume":"292","author":"Wang YY","year":"2022","unstructured":"Wang YY, Gao B, Yang Y, et al.. Histone deacetylase 3 suppresses the expression of SHP-1 via deacetylation of DNMT1 to promote heart failure. Life Sci. 2022, 292:119552. 10.1016\/j.lfs.2021.119552","journal-title":"Life Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1336551","article-title":"Cardiac fibrogenesis: an immuno-metabolic perspective","volume":"15","author":"Hoque MM","year":"2024","unstructured":"Hoque MM, Gbadegoye JO, Hassan FO, Raafat A, Lebeche D. Cardiac fibrogenesis: an immuno-metabolic perspective. Front Physiol. 2024, 15:1336551. 10.3389\/fphys.2024.1336551","journal-title":"Front Physiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00250.2023","article-title":"Regulation of cardiac fibroblasts by lymphocytes after a myocardial infarction: playing in the major league","volume":"325","author":"Learmonth M","year":"2023","unstructured":"Learmonth M, Corker A, Dasgupta S, DeLeon-Pennell KY. Regulation of cardiac fibroblasts by lymphocytes after a myocardial infarction: playing in the major league. Am J Physiol Heart Circ Physiol. 2023, 325:H553-61. 10.1152\/ajpheart.00250.2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.052399","article-title":"The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions","volume":"124","author":"Zhang W","year":"2011","unstructured":"Zhang W, Chancey AL, Tzeng HP, et al.. The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation. 2011, 124:2106-16. 10.1161\/CIRCULATIONAHA.111.052399","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010028","article-title":"Cell-based mechanosensation, epigenetics, and non-coding RNAs in progression of cardiac fibrosis","volume":"21","author":"Ferrari S","year":"2019","unstructured":"Ferrari S, Pesce M. Cell-based mechanosensation, epigenetics, and non-coding RNAs in progression of cardiac fibrosis. Int J Mol Sci. 2019, 21:28. 10.3390\/ijms21010028","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cells10050990","article-title":"Channelling the force to reprogram the matrix: mechanosensitive ion channels in cardiac fibroblasts","volume":"10","author":"Stewart L","year":"2021","unstructured":"Stewart L, Turner NA. Channelling the force to reprogram the matrix: mechanosensitive ion channels in cardiac fibroblasts. Cells. 2021, 10:990. 10.3390\/cells10050990","journal-title":"Cells"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.009167","article-title":"Mechanically activated Piezo1 channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase activity and interleukin-6 secretion","volume":"294","author":"Blythe NM","year":"2019","unstructured":"Blythe NM, Muraki K, Ludlow MJ, et al.. Mechanically activated Piezo1 channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase activity and interleukin-6 secretion. J Biol Chem. 2019, 294:17395-408. 10.1074\/jbc.RA119.009167","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158065","article-title":"Piezo1 channel as a potential target for hindering cardiac fibrotic remodeling","volume":"23","author":"Braidotti N","year":"2022","unstructured":"Braidotti N, Chen SN, Long CS, Cojoc D, Sbaizero O. Piezo1 channel as a potential target for hindering cardiac fibrotic remodeling. Int J Mol Sci. 2022, 23:8065. 10.3390\/ijms23158065","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091386","article-title":"Properties and functions of fibroblasts and myofibroblasts in myocardial infarction","volume":"11","author":"Venugopal H","year":"2022","unstructured":"Venugopal H, Hanna A, Humeres C, Frangogiannis NG. Properties and functions of fibroblasts and myofibroblasts in myocardial infarction. Cells. 2022, 11:1386. 10.3390\/cells11091386","journal-title":"Cells"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021212214","article-title":"The clinical significance of cardiac MRI late gadolinium enhancement in hypertrophic cardiomyopathy","volume":"302","author":"Hanneman K","year":"2022","unstructured":"Hanneman K. The clinical significance of cardiac MRI late gadolinium enhancement in hypertrophic cardiomyopathy. Radiology. 2022, 302:307-8. 10.1148\/radiol.2021212214","journal-title":"Radiology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.886553","article-title":"Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target","volume":"9","author":"Schimmel K","year":"2022","unstructured":"Schimmel K, Ichimura K, Reddy S, Haddad F, Spiekerkoetter E. Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target. Front Cardiovasc Med. 2022, 9:886553. 10.3389\/fcvm.2022.886553","journal-title":"Front Cardiovasc Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.6480","article-title":"Interrelationship between the myocardial mass, fibrosis, BNP, and clinical outcomes in hypertrophic cardiomyopathy","volume":"55","author":"Miyaji Y","year":"2016","unstructured":"Miyaji Y, Iwanaga Y, Nakamura T, Yasuda M, Kawamura T, Miyazaki S. Interrelationship between the myocardial mass, fibrosis, BNP, and clinical outcomes in hypertrophic cardiomyopathy. Intern Med. 2016, 55:1261-8. 10.2169\/internalmedicine.55.6480","journal-title":"Intern Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113904","article-title":"Fibrosis of the diabetic heart: clinical significance, molecular mechanisms, and therapeutic opportunities","volume":"176","author":"Tuleta I","year":"2021","unstructured":"Tuleta I, Frangogiannis NG. Fibrosis of the diabetic heart: clinical significance, molecular mechanisms, and therapeutic opportunities. Adv Drug Deliv Rev. 2021, 176:113904. 10.1016\/j.addr.2021.113904","journal-title":"Adv Drug Deliv Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-00905-9","article-title":"Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications","volume":"30","author":"Chen Y","year":"2024","unstructured":"Chen Y, Meng Z, Li Y, Liu S, Hu P, Luo E. Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications. Mol Med. 2024, 30:141. 10.1186\/s10020-024-00905-9","journal-title":"Mol Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-016-2445-3","article-title":"Reactive oxygen species and fibrosis: further evidence of a significant liaison","volume":"365","author":"Richter K","year":"2016","unstructured":"Richter K, Kietzmann T. Reactive oxygen species and fibrosis: further evidence of a significant liaison. Cell Tissue Res. 2016, 365:591-605. 10.1007\/s00441-016-2445-3","journal-title":"Cell Tissue Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s0008-6363(00)00044-4","article-title":"Angiotensin II, adhesion, and cardiac fibrosis","volume":"46","author":"Schnee J","year":"2000","unstructured":"Schnee J, Hsueh W. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res. 2000, 46:264-8. 10.1016\/s0008-6363(00)00044-4","journal-title":"Cardiovasc Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf2675","article-title":"A Thy-1-negative immunofibroblast population emerges as a key determinant of fibrotic outcomes to biomaterials","volume":"10","author":"Abebayehu D","year":"2024","unstructured":"Abebayehu D, Pfaff BN, Bingham GC, et al.. A Thy-1-negative immunofibroblast population emerges as a key determinant of fibrotic outcomes to biomaterials. Sci Adv. 2024, 10:eadf2675. 10.1126\/sciadv.adf2675","journal-title":"Sci Adv"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-023-02970-3","article-title":"Myocardial fibrosis associates with lupus anticoagulant in patients with systemic lupus erythematosus","volume":"40","author":"Myhr KA","year":"2024","unstructured":"Myhr KA, Zinglersen AH, Pecini R, Jacobsen S. Myocardial fibrosis associates with lupus anticoagulant in patients with systemic lupus erythematosus. Int J Cardiovasc Imaging. 2024, 40:127-37. 10.1007\/s10554-023-02970-3","journal-title":"Int J Cardiovasc Imaging"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.33963\/KP.a2023.0140","article-title":"Fibrosis-specific biomarkers and interstitial fibrosis in hypertrophic cardiomyopathy","volume":"81","author":"Correale M","year":"2023","unstructured":"Correale M, Santoro F, Magr\u00ec D. Fibrosis-specific biomarkers and interstitial fibrosis in hypertrophic cardiomyopathy. Kardiol Pol. 2023, 81:671-2. 10.33963\/KP.a2023.0140","journal-title":"Kardiol Pol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-1192","article-title":"Immunosuppressive therapy in myocarditis","volume":"79","author":"Frustaci A","year":"2015","unstructured":"Frustaci A, Chimenti C. Immunosuppressive therapy in myocarditis. Circ J. 2015, 79:4-7. 10.1253\/circj.CJ-14-1192","journal-title":"Circ J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.972301","article-title":"Thin filament cardiomyopathies: a review of genetics, disease mechanisms, and emerging therapeutics","volume":"9","author":"Keyt LK","year":"2022","unstructured":"Keyt LK, Duran JM, Bui QM, et al.. Thin filament cardiomyopathies: a review of genetics, disease mechanisms, and emerging therapeutics. Front Cardiovasc Med. 2022, 9:972301. 10.3389\/fcvm.2022.972301","journal-title":"Front Cardiovasc Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx596","article-title":"Lamin A\/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation","volume":"39","author":"Hasselberg NE","year":"2018","unstructured":"Hasselberg NE, Haland TF, Saberniak J, et al.. Lamin A\/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J. 2018, 39:853-60. 10.1093\/eurheartj\/ehx596","journal-title":"Eur Heart J"},{"key":"ref40","article-title":"Aging and cardiac fibrosis","volume":"2","author":"Biernacka A","year":"2011","unstructured":"Biernacka A, Frangogiannis NG. Aging and cardiac fibrosis. Aging Dis. 2011, 2:158-73.","journal-title":"Aging Dis"},{"key":"ref41","article-title":"Chemotherapy agents that cause cardiotoxicity","volume":"42","author":"Thomas SA","year":"2017","unstructured":"Thomas SA. Chemotherapy agents that cause cardiotoxicity. US Pharm. 2017, 42:24-33.","journal-title":"US Pharm"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.190512","article-title":"Aldosterone inhibits antifibrotic factors in mouse hypertensive heart","volume":"59","author":"Azibani F","year":"2012","unstructured":"Azibani F, Benard L, Schlossarek S, et al.. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension. 2012, 59:1179-87. 10.1161\/HYPERTENSIONAHA.111.190512","journal-title":"Hypertension"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-013-0354-3","article-title":"Aldosterone mediates cardiac fibrosis in the setting of hypertension","volume":"15","author":"Azibani F","year":"2013","unstructured":"Azibani F, Fazal L, Chatziantoniou C, Samuel JL, Delcayre C. Aldosterone mediates cardiac fibrosis in the setting of hypertension. Curr Hypertens Rep. 2013, 15:395-400. 10.1007\/s11906-013-0354-3","journal-title":"Curr Hypertens Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.116","article-title":"Senescent cells: an emerging target for diseases of ageing","volume":"16","author":"Childs BG","year":"2017","unstructured":"Childs BG, Gluscevic M, Baker DJ, Laberge RM, Marquess D, Dananberg J, van Deursen JM. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov. 2017, 16:718-35. 10.1038\/nrd.2017.116","journal-title":"Nat Rev Drug Discov"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeac242","article-title":"Emerging molecular imaging targets and tools for myocardial fibrosis detection","volume":"24","author":"Barton AK","year":"2023","unstructured":"Barton AK, Tzolos E, Bing R, et al.. Emerging molecular imaging targets and tools for myocardial fibrosis detection. Eur Heart J Cardiovasc Imaging. 2023, 24:261-75. 10.1093\/ehjci\/jeac242","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2018.06.001","article-title":"Assessment of myocardial fibrosis using T1-mapping and extracellular volume measurement on cardiac magnetic resonance imaging for the diagnosis of radiation-induced cardiomyopathy","volume":"18","author":"Mukai-Yatagai N","year":"2018","unstructured":"Mukai-Yatagai N, Haruki N, Kinugasa Y, et al.. Assessment of myocardial fibrosis using T1-mapping and extracellular volume measurement on cardiac magnetic resonance imaging for the diagnosis of radiation-induced cardiomyopathy. J Cardiol Cases. 2018, 18:132-5. 10.1016\/j.jccase.2018.06.001","journal-title":"J Cardiol Cases"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12461-w","article-title":"Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET\/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial","volume":"24","author":"Bentestuen M","year":"2024","unstructured":"Bentestuen M, Ladekarl M, Knudsen A, Zacho HD. Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET\/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial. BMC Cancer. 2024, 24:699. 10.1186\/s12885-024-12461-w","journal-title":"BMC Cancer"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910865","article-title":"Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?","volume":"12","author":"Sweeney M","year":"2020","unstructured":"Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. EMBO Mol Med. 2020, 12:e10865. 10.15252\/emmm.201910865","journal-title":"EMBO Mol Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review","volume":"18","author":"Haaf P","year":"2016","unstructured":"Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016, 18:89. 10.1186\/s12968-016-0308-4","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-014-0539-y","article-title":"Characteristics and clinical relevance of late gadolinium enhancement in cardiac magnetic resonance in patients with systemic sclerosis","volume":"30","author":"Sano M","year":"2015","unstructured":"Sano M, Satoh H, Suwa K, et al.. Characteristics and clinical relevance of late gadolinium enhancement in cardiac magnetic resonance in patients with systemic sclerosis. Heart Vessels. 2015, 30:779-88. 10.1007\/s00380-014-0539-y","journal-title":"Heart Vessels"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.113.001144","article-title":"Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis","volume":"7","author":"Kuruvilla S","year":"2014","unstructured":"Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014, 7:250-8. 10.1161\/CIRCIMAGING.113.001144","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003517","article-title":"99mTc-HFAPi imaging identifies early myocardial fibrosis in the hypertensive heart","volume":"41","author":"Xie B","year":"2023","unstructured":"Xie B, Li L, Lin M, et al.. 99mTc-HFAPi imaging identifies early myocardial fibrosis in the hypertensive heart. J Hypertens. 2023, 41:1645-52. 10.1097\/HJH.0000000000003517","journal-title":"J Hypertens"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000024573.17293.23","article-title":"TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension","volume":"40","author":"Lindsay MM","year":"2002","unstructured":"Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension. 2002, 40:136-41. 10.1161\/01.hyp.0000024573.17293.23","journal-title":"Hypertension"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07442-3","article-title":"Pharmacological inhibition of P-Rex1\/Rac1 axis blocked angiotensin II-induced cardiac fibrosis","volume":"38","author":"Pan J","year":"2024","unstructured":"Pan J, Liu M, Su H, Hu H, Chen H, Ma L. Pharmacological inhibition of P-Rex1\/Rac1 axis blocked angiotensin II-induced cardiac fibrosis. Cardiovasc Drugs Ther. 2024, 38:861-72. 10.1007\/s10557-023-07442-3","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.crvasa.2013.06.003","article-title":"Possibilities of influencing the myocardial remodeling","volume":"55","author":"Hegarov\u00e1 M","year":"2013","unstructured":"Hegarov\u00e1 M, M\u00e1lek I. Possibilities of influencing the myocardial remodeling. Cor Va. 2013, 55:355-63. 10.1016\/j.crvasa.2013.06.003","journal-title":"Cor Va"},{"key":"ref56","article-title":"Telmisartan inhibited angiotensin II-induced collagen metabolic imbalance without directly targeting TGF-\u03b2 1\/Smad signaling pathway in cardiac fibroblasts","volume":"63","author":"Zhang Y","year":"2015","unstructured":"Zhang Y, Zhao NA, Wang JK, et al.. Telmisartan inhibited angiotensin II-induced collagen metabolic imbalance without directly targeting TGF-\u03b2 1\/Smad signaling pathway in cardiac fibroblasts. Minerva Cardioangiol. 2015, 63:507-14.","journal-title":"Minerva Cardioangiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872014000100010","article-title":"Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage [Article in Spanish]","volume":"142","author":"Verdugo FJ","year":"2014","unstructured":"Verdugo FJ, Montellano FA, Carre\u00f1o JE, Marusic ET. Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage [Article in Spanish]. Rev Med Chil. 2014, 142:61-71. 10.4067\/S0034-98872014000100010","journal-title":"Rev Med Chil"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1177\/1074248418795897","article-title":"Angiotensin-converting enzyme inhibitors provide better long-term survival benefits to patients with AMI than angiotensin II receptor blockers after survival hospital discharge","author":"Choi IS","year":"2018","unstructured":"Choi IS, Park IB, Lee K, et al.. Angiotensin-converting enzyme inhibitors provide better long-term survival benefits to patients with AMI than angiotensin II receptor blockers after survival hospital discharge. J Cardiovasc Pharmacol Ther. 2018, 1074248418795897. 10.1177\/1074248418795897","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00093.2018","article-title":"Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2\/MMP-9 expression in diabetic rats","volume":"315","author":"Li G","year":"2018","unstructured":"Li G, Xing W, Zhang M, et al.. Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2\/MMP-9 expression in diabetic rats. Am J Physiol Heart Circ Physiol. 2018, 315:H802-13. 10.1152\/ajpheart.00093.2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26030915","article-title":"Plant polyphenols as heart's best friends: from health properties, to cellular effects, to molecular mechanisms of action","volume":"26","author":"Stankovic S","year":"2025","unstructured":"Stankovic S, Mutavdzin Krneta S, Djuric D, Milosevic V, Milenkovic D. Plant polyphenols as heart's best friends: from health properties, to cellular effects, to molecular mechanisms of action. Int J Mol Sci. 2025, 26:915. 10.3390\/ijms26030915","journal-title":"Int J Mol Sci"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042178","article-title":"A novel role of cyclic nucleotide phosphodiesterase 10A in pathological cardiac remodeling and dysfunction","volume":"141","author":"Chen S","year":"2020","unstructured":"Chen S, Zhang Y, Lighthouse JK, et al.. A novel role of cyclic nucleotide phosphodiesterase 10A in pathological cardiac remodeling and dysfunction. Circulation. 2020, 141:217-33. 10.1161\/CIRCULATIONAHA.119.042178","journal-title":"Circulation"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103370","article-title":"TNAP is a novel regulator of cardiac fibrosis after myocardial infarction by mediating TGF-\u03b2\/Smads and ERK1\/2 signaling pathways","volume":"67","author":"Cheng X","year":"2021","unstructured":"Cheng X, Wang L, Wen X, et al.. TNAP is a novel regulator of cardiac fibrosis after myocardial infarction by mediating TGF-\u03b2\/Smads and ERK1\/2 signaling pathways. EBioMedicine. 2021, 67:103370. 10.1016\/j.ebiom.2021.103370","journal-title":"EBioMedicine"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.124.325017","article-title":"A vaccine against fibroblast activation protein improves murine cardiac fibrosis by preventing the accumulation of myofibroblasts","volume":"136","author":"Yoshida S","year":"2025","unstructured":"Yoshida S, Hayashi H, Kawahara T, et al.. A vaccine against fibroblast activation protein improves murine cardiac fibrosis by preventing the accumulation of myofibroblasts. Circ Res. 2025, 136:26-40. 10.1161\/CIRCRESAHA.124.325017","journal-title":"Circ Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104274","article-title":"Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling","volume":"85","author":"Zhou Q","year":"2022","unstructured":"Zhou Q, Meng D, Li F, et al.. Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling. EBioMedicine. 2022, 85:104274. 10.1016\/j.ebiom.2022.104274","journal-title":"EBioMedicine"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104108","article-title":"Targeting miR-30d reverses pathological cardiac hypertrophy","volume":"81","author":"Li J","year":"2022","unstructured":"Li J, Sha Z, Zhu X, et al.. Targeting miR-30d reverses pathological cardiac hypertrophy. EBioMedicine. 2022, 81:104108. 10.1016\/j.ebiom.2022.104108","journal-title":"EBioMedicine"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1186\/s13619-023-00182-7","article-title":"Harnessing stem cell and lineage reprogramming technology to treat cardiac fibrosis","volume":"12","author":"Zeng N","year":"2023","unstructured":"Zeng N, Tang W, Wu Y, Fan H, Xie S, Cao N. Harnessing stem cell and lineage reprogramming technology to treat cardiac fibrosis. Cell Regen. 2023, 12:39. 10.1186\/s13619-023-00182-7","journal-title":"Cell Regen"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1051\/epjconf\/202430902004","article-title":"Organisms-on-a-chip","author":"Raimondi MT","year":"2024","unstructured":"Raimondi MT. Organisms-on-a-chip. EPJ Web of Conferences. 2024. 309:10.1051\/epjconf\/202430902004"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.045115","article-title":"High-resolution transcriptomic profiling of the heart during chronic stress reveals cellular drivers of cardiac fibrosis and hypertrophy","volume":"142","author":"McLellan MA","year":"2020","unstructured":"McLellan MA, Skelly DA, Dona MS, et al.. High-resolution transcriptomic profiling of the heart during chronic stress reveals cellular drivers of cardiac fibrosis and hypertrophy. Circulation. 2020, 142:1448-63. 10.1161\/CIRCULATIONAHA.119.045115","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/348675-causes-diagnosis-treatment-and-prognosis-of-cardiac-fibrosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T07:41:14Z","timestamp":1743061274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/348675-causes-diagnosis-treatment-and-prognosis-of-cardiac-fibrosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":68,"URL":"https:\/\/doi.org\/10.7759\/cureus.81264","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}